Abbott Laboratories (NYSE:ABT) recently posted second quarter results that beat expectations, albeit slightly. Spinning off the company's pharmaceutical arm into AbbVie exposed a bloated, underperforming giant. Fortunately, the company is making strides to boost profitability and increase its presence in quickly growing markets.
The Street likes the results so far. Watch the slideshow to see if Abbott Labs can continue to impress in the quarters to come.
Is Abbott Labs a top dividend stock for the next decade?
The smartest investors know that dividend stocks like Abbott Labs simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.
Cory Renauer owns shares of Abbott Laboratories. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.